$EW · Edwards Lifesciences Corp
Edwards Lifesciences reported Q3 2026 results (quarter ended September 30, 2026) via an 8-K Item 2.02 press release. Net sales rose 10.5% to $1.72B (11.2% constant currency), with TAVR sales up 8.0% to $1.24B and TMTT up 44.0% to $207M. GAAP EPS was $0.53; adjusted EPS was $0.80, up 19% YoY. The company raised FY2026 sales growth guidance to ~11.5% (from 10–11%), TAVR growth to 9.0–9.5%, TMTT to $780–$790M, and adjusted EPS to $2.97–$3.05.
- Q3 net sales $1.72B, up 10.5% YoY (11.2% constant currency).
- TAVR sales $1.24B, up 8.0%; TMTT sales $207M, up 44.0%.
- Adjusted EPS $0.80, up 19% YoY; GAAP EPS $0.53.
- FY26 adjusted EPS guidance raised to $2.97–$3.05 from $2.95–$3.05.
- Q3 included $220.2M impairment of intangible and long-lived assets.
Extended-hours last trade $101.88, up 2.53% vs regular close ($99.37), reflecting a positive reaction to the beat and raised guidance.
A broad-based beat with raised full-year guidance across sales, TAVR, TMTT, and EPS signals durable structural heart momentum.
Strong TMTT growth (44%) and TAVR share stability reinforce Edwards' structural heart leadership amid rising competition in transcatheter valve markets.
Q3 included a $220.2M impairment of intangible and long-lived assets, and growth is expected to shift from share gains to procedure volumes in Q4.